AustraliaHealth

Clinical dermatology leader Botanix Pharmaceuticals (ASX:BOT) has secured firm commitments to raise approximately $45 million in new capital.

Rhythm Biosciences (ASX:RHY) entered into a strategic distribution service agreement with 4Cyte Pathology, one of Australia's largest independent pathology providers.

Australian Clinical Labs (ASX:ACL) announced its financial results for the first half of fiscal year 2026, showcasing a strategic shift toward "earnings quality".

BTC Health (ASX:BTC) landed an exclusive multi-year distribution agreement with global blood purification leader, Jafron Biomedical.

Bio-Gene Technology (ASX:BGT) has commenced a critical acute neurotoxicity study for its flagship nature-derived insecticide, Flavocide.

Osteopore (ASX:OSX), a pioneer in regenerative medicine, announced an exclusive distribution partnership with Medprin Biotech to penetrate the Latin American market.

AVITA Medical (ASX:AVH) reported a "year of stabilisation" with 2025 revenue rising 11% to US$71.6 million.

The Australian Competition and Consumer Commission has formally approved Ramsay Health Care's (ASX:RHC) acquisition of the National Capital Private Hospital.

Cochlear (ASX:COH) booked a 9% dip in underlying profit for H1 FY26, balancing the landmark Nucleus Nexa System launch against fiscal tightening and R&D costs.

Mesoblast (ASX:MSB) unveiled new data at the 2026 tandem meetings of the ASTCT and CIBMTR, reinforcing the efficacy of Ryoncil.

Clinical-stage biotechnology firm Entropy Neurodynamics (ASX:ENP) has announced a major strategic victory with the granting of an Australian patent for its proprietary psychedelic administration method.

Therapeutic antibody developer Patrys (ASX:PAB) appointed Dr. Samantha South as its new CEO, effective Feb. 16.